Advice
following an abbreviated submission:
somapacitan (Sogroya®) is accepted for restricted use within NHSScotland.
Indication under review: for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD).
SMC restriction: for children aged 3 years and above and adolescents with growth failure due to growth hormone deficiency (paediatric GHD).
Somapacitan offers an additional treatment choice in the therapeutic class of recombinant human growth hormones for this indication.
Download detailed advice270KB (PDF)
Medicine details
- Medicine name:
- somapacitan (Sogroya)
- SMC ID:
- SMC2629
- Indication:
- Pharmaceutical company
- Novo Nordisk Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 11 November 2024